Home
Beacon Therapeutics Limited

Beacon Therapeutics Limited Market Share Analysis for May 2026

Gene therapy offers hope by repairing genetic flaws, enhancing the body's natural healing abilities, and improving the quality of life.

Industry: N/A

Domainbeacontx.com

Year Founded2023

Employees51 - 200

Annual Revenue< $1M

Beacon Therapeutics Limited

Beacon Therapeutics Limited (including company regionals)

beacontx.com

See more website traffic and engagement information

Total visits to Beacon Therapeutics Limited's top domains

Understand Beacon Therapeutics Limited market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

beacontx.com6.5K

See more with Sales Intelligence

Avg. visit duration in Beacon Therapeutics Limited's top domains

Analyze Beacon Therapeutics Limited engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

beacontx.com00:00:07

See more with Sales Intelligence

Avg. pageviews on Beacon Therapeutics Limited's top domains

See how Beacon Therapeutics Limited keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

beacontx.com1.62

See more with Sales Intelligence

Beacon Therapeutics Limited top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Beacon Therapeutics Limited

These are the website technologies, by industry, used by Beacon Therapeutics Limited top domains

Widget (3)

Twemoji

Conversion & Analytics (2)

Google Analytics

Mobile (2)

Meta Viewport

Advertising (1)

FirstImpression

More Technologies

5

See all

News & Signals from Beacon Therapeutics Limited

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsBeacon Therapeutics Limited attended event Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting on May 3rd '26.Beacon Therapeutics has announced positive 12-month safety and efficacy results from the phase 2 DAWN trial of laruparetigene zovaparvovec (laru-zova) in patients with X-linked retinitis pigmentosa (XLRP), presenting the data in an oral session at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, held in Denver, Colorado, from May 3-7, 2026.

NewsBeacon Therapeutics Limited is developing BTX-001.Researchers from Beacon Therapeutics Holdings Ltd. reported the development of BTX-001, an intravitreal gene therapy designed to target the complement pathway through delivery of a C5 inhibitor.

NewsBeacon Therapeutics Limited hires Colin Walsh as Board of Directors.Beacon Therapeutics also appointed Colin Walsh, PhD, Managing Director, Life Sciences at Goldman Sachs Alternatives, to its Board of Directors.